BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15257418)

  • 1. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
    Stahl A; Ott K; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.
    Stahl A; Ott K; Weber WA; Becker K; Link T; Siewert JR; Schwaiger M; Fink U
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):288-95. PubMed ID: 12552348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
    Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial.
    Krak NC; Boellaard R; Hoekstra OS; Twisk JW; Hoekstra CJ; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):294-301. PubMed ID: 15791438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
    Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction.
    Lonneux M; Borbath I; Bol A; Coppens A; Sibomana M; Bausart R; Defrise M; Pauwels S; Michel C
    Eur J Nucl Med; 1999 Jun; 26(6):591-8. PubMed ID: 10369944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
    Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
    J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
    Lin C; Itti E; Haioun C; Petegnief Y; Luciani A; Dupuis J; Paone G; Talbot JN; Rahmouni A; Meignan M
    J Nucl Med; 2007 Oct; 48(10):1626-32. PubMed ID: 17873129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of iterative reconstruction (OSEM) versus filtered back-projection for the assessment of myocardial glucose uptake and myocardial perfusion using dynamic PET.
    Søndergaard HM; Madsen MM; Boisen K; Bøttcher M; Schmitz O; Nielsen TT; Bøtker HE; Hansen SB
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):320-9. PubMed ID: 17033850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of F18-FDG PET radiomic features for different cervical tumor segmentation methods, gray-level discretization, and reconstruction algorithms.
    Altazi BA; Zhang GG; Fernandez DC; Montejo ME; Hunt D; Werner J; Biagioli MC; Moros EG
    J Appl Clin Med Phys; 2017 Nov; 18(6):32-48. PubMed ID: 28891217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection.
    Ramos CD; Erdi YE; Gonen M; Riedel E; Yeung HW; Macapinlac HA; Chisin R; Larson SM
    Eur J Nucl Med; 2001 Feb; 28(2):155-64. PubMed ID: 11303885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
    Tixier F; Le Rest CC; Hatt M; Albarghach N; Pradier O; Metges JP; Corcos L; Visvikis D
    J Nucl Med; 2011 Mar; 52(3):369-78. PubMed ID: 21321270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
    Ott K; Herrmann K; Schuster T; Langer R; Becker K; Wieder HA; Wester HJ; Siewert JR; zum Büschenfelde CM; Buck AK; Wilhelm D; Ebert MP; Peschel C; Schwaiger M; Lordick F; Krause BJ
    Ann Surg Oncol; 2011 Nov; 18(12):3316-23. PubMed ID: 21537865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.